Pharmacologic Advancement in Schizophrenia
DOI:
https://doi.org/10.51985/JBUMDC2020016Keywords:
Antipsychotic drug, Schizophrenia, Pathophysiology, Neurotransmitter systemAbstract
Schizophrenia is a disorder of mental debility characterized by abnormal social behavior in which person is unable to
recognize reality. The sign and symptoms are variable and heterogeneous. Due to the diverse symptoms and variable
treatment response, it is challenging to treat. Recent advancements in genomic, epidemiology and neurosciences can
provide the appropriate medicines and treatments for minimizing symptoms and consequences of schizophrenia. This
literature review was highlights the etiology, pathophysiology, neurotransmitter system, novel treatment and management
of schizophrenia.The mainstay treatment of schizophrenic patients included antipsychotic drug with psychotherapy, social
rehabilitation and job training.
References
Page CE, Coutellier L. Reducing inhibition: A promising new strategy for the treatment of schizophrenia. EBioMedicine. 2018;35:25-26.
Pestana-Santos A, Loureiro L, Santos V, Carvalho I. Patients with schizophrenia assessing psychiatrists’ communication skills. Psychiatry Res. 2018;269:13-20. doi:10.1016/j.psychres.2018.08.040
Zhou J, Millier A, Toumi M. Systematic review of pharmacoeconomic models for schizophrenia. J Mar Acc Heal Pol. 2018;6(1):1508272.
Leroux E, Vandevelde A, Tréhout M, Dollfus S. Abnormalities of fronto-subcortical pathways in schizophrenia and the differential impacts of antipsychotic treatment: a DTI-based tractography study. Psych Res - Neuro. 2018;280:22-29.
Turns DF. Epidemiology of schizophrenia. Ann Med Psychol. 1980;138(6):637-646.
Lindström E. Review of The Epidemiology of Schizophrenia. Eur Child Adolesc Psychiatry. 2004;13(6):402.
Brain C, Kymes S, DiBenedetti DB, Brevig T, Velligan DI. Experiences, attitudes, and perceptions of caregivers of individuals with treatment-resistant schizophrenia: A qualitative study. BMC Psychiatry. 2018;18(1):1-13. doi:10.1186/s12888- 018-1833-5
Azmanova M, Pitto-Barry A, Barry NPE. Schizophrenia: Synthetic strategies and recent advances in drug design. Medchemcomm. 2018;9(5):759-782.
Mote J, Grant PM, Silverstein SM. Treatment Implications of Situational Variability in Cognitive and Negative Symptoms of Schizophrenia. 2018;69(10):1095-1097.
Stummer L, Markovic M, Maroney M. Pharmacologic Treatment Options for Insomnia in Patients with Schizophrenia. Medicines. 2018;5(3):88.
Kantrowitz J, Citrome L, Javitt D. GABAB receptors, schizophrenia and sleep dysfunction: A review of the relationship and its potential clinical and therapeutic implications. CNS Drugs. 2009;23: 681–691.
Cadena EJ, White DM, Kraguljac N V. Cognitive control network dysconnectivity and response to antipsychotic treatment in schizophrenia. Schizophr Res. 2018. doi:10.1016/j.schres.2018.07.045
Santos A, Santos V. Patients with schizophrenia assessing psychiatrists’ communication skills. Europ Journal Com. 2018;269:13-20. doi:10.1016/J.PSYCHRES.2018.08.040
Du X, Choa F-S, Chiappelli J. Aberrant Middle Prefrontal- Motor Cortex Connectivity Mediates Motor Inhibitory Biomarker in Schizophrenia. Biol Psychiatry. 2019;85(1):49- 59. doi:10.1016/j.biopsych.2018.06.007
Eftekharian MM, Omrani MD, Arsang-Jang S, Taheri M, Ghafouri-Fard S. Serum cytokine profile in schizophrenic patients. Hum Antibodies. 2018;1:1-7. doi:10.3233/HAB- 180344
Du X, Choa F Sen, Chiappelli J. Aberrant Middle Prefrontal- Motor Cortex Connectivity Mediates Motor Inhibitory Biomarker in Schizophrenia. Biol Psychiatry.2019; 85(1): 49–59.
Jagsch C, Hofer A. Erkrankungen des schizophrenen Formenkreisesim Alter. Z GerontolGeriatr. 2018;51(7):744- 49. doi:10.1007/s00391-018-1436-2
Orlovska W S, Köhler F, Brix S W, Nordentoft M , Kondziella D, Krogh J etal. Cerebrospinal fluid markers of inflammation and infections in schizophrenia and affective disorders: a systematic review and meta-analysis. Mol Psychiatry. 2019
;24(6):869-887.
Young AH, Blackwood DHR, Roxborough H, McQueen JK, Martin MJ, Kean D. A magnetic resonance imaging study of schizophrenia: Brain structure and clinical symptoms. Br J Psychiatry. 1991;158:158-164. doi:10.1192/bjp.158.2.158
Antonova E, Sharma T, Morris R, Kumari V. The relationship between brain structure and neurocognition in schizophrenia: A selective review. Schizophr Res. 2004;70(2-3):117-145. doi:10.1016/j.schres.2003.12.002
Hahn B, Robinson BM, Leonard CJ, Luck SJ, Gold JM. Posterior Parietal Cortex Dysfunction Is Central to Working Memory Storage and Broad Cognitive Deficits in Schizophrenia. J Neurosci. 2018;38(39):8378-87. doi:10.1523/JNEUROSCI.0913-18.2018
Lagger N, Amering M, Sibitz I, Gmeiner A, Schrank B. Stability and mutual prospective relationships of stereotyped beliefs about mental illness, hope and depressive symptoms among people with schizophrenia spectrum disorders. Psychiatry Res. 2018;268:484-489. doi:10.1016/j.psychres.2018.08.010
Strzelecki D, Ka³uzyñska O, Wysokiñski A. BDNF serum levels in schizophrenic patients during treatment augmentation with sarcosine. Psychiatry Res. 2016;242:54-60. doi:10.1016/j.psychres.2016.05.019
Grace AA. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia. Neuroscience. 1991;41(1):1- 24. doi:10.1016/0306-4522(91)90196-U
Carter CJ. Schizophrenia susceptibility genes converge on interlinked pathways related to glutamatergic transmission and long-term potentiation, oxidative stress and oligodendrocyte viability. Schizophr Res. 2006;86(1-3):1-14. doi:10.1016/j.schres.2006.05.023
Lawrie SM, Whalley HC, Abukmeil SS. Brain structure, genetic liability, and psychotic symptoms in subjects at high risk of developing schizophrenia. Biol Psychiatry. 2001;49(10):811-823. doi:10.1016/S0006-3223(00)01117-3
Tienari P, Sorri A, Lahti I. Genetic and psychosocial factors in schizophrenia: The Finnish adoptive family study. Schizophr Bull. 1987;13(3):477-484. doi:10.1093/schbul/13.3.477
Walsh T, McClellan JM, McCarthy SE. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science (80- ). 2008;320(5875):539-543. doi:10.1126/science.1155174
Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence. Mol Psychiatry. 2005;10(1):40-68. doi:10.1038/ sj.mp.4001558
Cosentino M, Fielta A , Caldiroli E, Marino F, Rispoli L, Comelli M etal. Assessment of lymphocyte subsets and neutrophil leukocyte function in chronic psychiatric patient on long term drug therapy. 1996; 20: 1117–29.
Cullen AE, Holmes S, Pollak TA. Associations Between Non- Neurological Autoimmune Disorders and Psychosis: A Meta- Analysis. Biol Psychiatry. 2018. doi:10.1016/ j.biopsych. 2018.06.016
Barlati S, Deste G, Ariu C, Vita A. Autism spectrum disorder and schizophrenia: Do they overlap? Int J EmergMent Health. 2016;18(1):760-763. doi:10.1192/apt.bp.115.014720
Medina R De, Bergh V Den. Prenatal maternal stress Prenatal maternal stress?: effects on pregnancy and the (unborn) child. 2002;70:3-14.
Leucht S, Burkard T, Henderson JH, Maj M, Sartorius N. Physical illness and schizophrenia: A review of the evidence. PhysIllnSchizophr A Rev Evid. 2007:1-208. doi:10.1017/CBO9780511543951
Edwards NC, Muser E, Doshi D. The threshold rate of oral atypical anti-psychotic adherence at which pali- peridonepalmitate is cost saving. J Med Econ. 2012;15:623–634.
Németh B, Fasseeh A, Molnár A, et al. A systematic review of health economic models and utility estimation methods in schizophrenia. Expert Rev Pharmacoecon Outcomes Res. 2018; 18(3): 267–75.
Einarson TR, Vicente C, Zilbershtein R, et al. Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden. Nord J Psychiatry. 2014;68:416–27.
Cantor-graae E. The contribution of social factors to the development of schizophrenia. 2007;52(5).
Alan S. Brown, Paul H. Patterson, Maternal Infection and Schizophrenia: Implications for Prevention.Schizophr Bull. 2011; 37(2): 284–29.
Ascher-Svanum H, Furiak NM, Lawson AH, et al. Cost- effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the USA. J Med Econ. 2012;15:531–47
Strand KB, Chisholm D, Fekadu A, et al. Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis. Health Policy Plan. 2016;31:504–13
Jones S, Castle DJ. Management of treatment resistant schizophrenia. South African Psychiatry Rev. 2006;9(1):17- 23. doi:10.4314/ajpsy.v9i1.30202
Zipursky RB. Rapid remission of first-episode schizophrenia with standardised treatment. The Lancet Psychiatry. 2018;0366(18):9-10.
Suzuki H, Hibino H, Inoue Y, Takaya A. Comparisons of the effects of second-generation antipsychotics long-acting injections on treatment retention according to severity of patient condition. Asian J Psychiatr. 2018;37(April):64-66. doi:10.1016/j.ajp.2018.08.009
Miller R. Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part I. CurrNeuropharmacol., 2009;7: 302- 14
Choi KM, Choi S, Hong JK, Lee MH, Jung JH. The Effects of Continuation-Maintenance Electroconvulsive Therapy on Reducing Hospital Re-Admissions in Patients with Treatment- Resistant Schizophrenia Clinical Characteristics of Participants. 2018;16(3):339-342.
Dobson D J, McDougall G, Busheikin J, Aldous J. Effects of social skills training and social milieu treatment on symptoms of schizophrenia. Psychiatric Services.1995; 46(4):376-380.
Hogarty GE, Kornblith S J,Greenwald D, DiBarry A L, Cooley S, Flesher S, etal. Personal therapy: A disorder-relevant psychotherapy for schizophrenia. Schizophrenia Bulletin. 1995; 21(3):379-93
Jack E, Scott D.Psychological Interventions for Schizophrenia Schizophrenia Bulletin. 1995;21(4): 621-30.
Jacqueline C.Mind the Gap: Bridging the Translational Gap in the Management of Schizophrenia by Treating the Whole Person.Med Rese Arch.2020;8(1):2-13.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Hafiza Tuseef Sayyar, Afshan Siddiq
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of Bahria University Medical & Dental College is an open access journal and is licensed under CC BY-NC 4.0. which permits unrestricted non commercial use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0 
